Westminster, Colorado, U.S., October 5, 2026
Cerapedics, an orthobiologics company focused on bone repair and fusion technologies, announced that its PearlMatrix® P-15 Peptide Enhanced Bone Graft has received a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS). The payment designation represents an important reimbursement milestone for the advanced bone-graft technology and is intended to support hospitals using eligible new technologies for Medicare patients. PearlMatrix combines P-15 peptide technology with a bone-graft matrix designed to support bone formation and spinal fusion. The CMS decision could improve access to the technology for eligible Medicare beneficiaries while providing hospitals with additional reimbursement support during its early adoption period.
PearlMatrix Receives CMS NTAP Designation
The New Technology Add-on Payment program is designed to provide additional Medicare reimbursement for qualifying new medical technologies that meet specific CMS requirements. Under the program, eligible technologies can receive payments in addition to standard diagnosis-related group reimbursement when they are used for qualifying Medicare cases. For Cerapedics, receiving NTAP status for PearlMatrix P-15 represents recognition of the technology’s clinical and innovative characteristics within the Medicare reimbursement framework. The designation may help address financial barriers that can arise when hospitals consider adopting newer medical technologies whose costs may not be fully reflected in existing payment systems. PearlMatrix is an advanced bone graft substitute that incorporates Cerapedics’ P-15 peptide technology. P-15 is a synthetic peptide designed to mimic a portion of the cell-binding domain of type I collagen, an important structural protein in bone. The technology is intended to support cellular attachment and bone formation as part of the bone-healing process.
P-15 Technology Supports Bone Formation
Bone graft materials play an important role in procedures where new bone growth is required, including spinal fusion surgery and other orthopedic applications. Successful fusion depends on the development of new bone across the intended fusion site, making the biological properties of graft materials an important consideration for surgeons. The P-15 peptide incorporated into Cerapedics’ technology is designed to interact with bone-forming cells and support processes associated with new bone formation. PearlMatrix combines this biological approach with a specialized graft matrix intended to provide a framework for bone growth. The technology is part of a broader shift in orthobiologics toward products that do more than simply provide structural material. Researchers and medical-device companies are increasingly developing bioactive bone graft technologies designed to interact with biological pathways involved in healing. Such approaches may provide surgeons with additional options for supporting bone regeneration in appropriately selected patients. The CMS payment decision provides an important commercial development for Cerapedics as it continues to expand the availability of its orthobiologic technologies. Reimbursement support can be particularly important for hospitals evaluating innovative products for complex surgical procedures.
Advertisement
Medicare Payment Could Support Broader Adoption
The NTAP designation could help facilitate hospital adoption of PearlMatrix by providing additional Medicare reimbursement for qualifying cases. Access to appropriate reimbursement is an important factor in the adoption of new medical technologies because hospitals must balance clinical needs with operational and financial considerations. For patients undergoing procedures requiring bone grafting, broader access to advanced orthobiologic technologies could provide physicians with additional treatment options. However, reimbursement designation does not itself establish superiority over other bone graft products, and clinical decisions remain dependent on individual patient circumstances and physician judgment.
Cerapedics’ latest reimbursement milestone also highlights the growing importance of the intersection between medical-device innovation, clinical evidence, and healthcare economics. As new orthobiologic technologies enter the market, regulatory clearance and clinical performance are increasingly accompanied by efforts to establish appropriate reimbursement pathways. The NTAP decision therefore represents a significant development for Cerapedics and the broader orthobiologics and MedTech industry, potentially supporting the continued adoption of innovative bone-healing technologies in U.S. healthcare.
Source: Cerapedics press release
